Hong Kong Endometrial Receptivity Array (ERA): Indications, Procedure, and Clinical Value

Real Consultation Scenario — “Doctor, I have already transferred high-quality blastocysts three times. My endometrial thickness is always above 8mm, and my hormone levels are normal, but implantation has never occurred. Do I need an ERA test? Is it convenient to have this test done in Hong Kong?” This is one of the most common questions asked by patients with recurrent implantation failure in reproductive clinics. Endometrial Receptivity Array (ERA) testing is precisely integrated into clinical decision-making pathways in such challenging situations.

1. What is Endometrial Receptivity Array (ERA)?

Endometrial Receptivity Array (ERA) is a molecular diagnostic technology based on gene expression profiling. By analyzing the expression levels of 236 genes related to receptivity in an endometrial tissue sample, it determines the functional state of the endometrium, thereby identifying the “optimal timing” for embryo transfer — the Window of Implantation.

The core value of ERA testing is: Identifying whether the window of implantation is displaced. Approximately 20%–25% of patients with recurrent implantation failure have an advanced or delayed window of implantation. Transferring at the conventional time can lead to embryo-endometrial asynchrony, a significant cause of implantation failure.

2. Indications: When Should ERA Testing Be Considered?

ERA testing is not suitable for all patients undergoing IVF. In clinical practice, the following groups are considered appropriate candidates for evaluation:

• Recurrent Implantation Failure: Failure to implant after ≥2 transfers of good-quality embryos, especially at the blastocyst stage.
• Previous Transfer at a Defined Time but No Implantation: Failed transfer at the standard time (e.g., day 6–7 after ovulation) after excluding embryonic factors, uterine anatomical abnormalities, and immune factors.
• Thin or Morphologically Abnormal Endometrium: Endometrial thickness is adequate but implantation repeatedly fails, requiring assessment of endometrial functional status.
• Unexplained Infertility: No clear cause found after comprehensive evaluation, and implantation fails in a conventional IVF cycle.

When ERA Testing is Generally Not Recommended as a First Priority:

• First transfer with good embryo quality and normal endometrial conditions.
• Presence of untreated intrauterine pathology (e.g., polyps, adhesions, fibroids).
• Embryo factors not ruled out (e.g., chromosomal abnormalities, poor developmental potential).
• Insufficient optimization of the endometrial preparation protocol.

3. Specific Procedure for ERA Testing in Hong Kong

The ERA testing procedure in Hong Kong is largely consistent with that in Mainland China and overseas. The main difference lies in the laboratory where the sample is sent for analysis. Currently, most Hong Kong fertility centers send samples to the IGENOMIX laboratory in Spain or related laboratories in the United States, while some centers use local collaborative testing platforms.

3.1 Endometrial Preparation Phase

Patients must first complete a full “mock transfer cycle” for endometrial preparation. Two common protocols are used:

The choice between the two protocols depends on the patient’s ovulatory function, previous endometrial response, and the physician’s clinical preference. The HRT protocol is more widely used for ERA preparation due to better timing control.

3.2 Endometrial Biopsy Sampling

At a specific time point after progesterone exposure (typically day 5–7 after progesterone administration, or day 6–8 after ovulation in a natural cycle), the physician uses a thin, flexible catheter inserted through the cervix into the uterine cavity to gently aspirate a small piece of endometrial tissue. The entire procedure takes about 30–60 seconds, requires no anesthesia, and most patients experience only mild cramping or discomfort.

3.3 Sample Shipping and Genetic Analysis

The obtained endometrial tissue sample is processed, preserved at low temperature, and sent to the testing laboratory. The laboratory extracts RNA and analyzes the expression profile of 236 receptivity-related genes using gene chip or sequencing technology. This profile is compared against a reference model in the database to determine the endometrial state.

3.4 Report Interpretation and Transfer Protocol Adjustment

The test report typically includes:

• Classification of the endometrial molecular state (Receptive / Non-receptive / Displaced Window).
• If a displaced window is identified, a recommended adjustment to the transfer timing (e.g., advancing or delaying by 24–48 hours).
• Some reports include a gene expression heatmap and comparison with the reference population.

Based on the report, the physician adjusts the progesterone exposure time in the subsequent formal transfer cycle to synchronize embryo transfer with the individualized window of implantation.

4. Testing Timeline and Cycle Arrangement

From the start of endometrial preparation to receiving ERA results, the following timeline is typically involved:

Overall Cycle: From initiating endometrial preparation to obtaining results and formulating a transfer plan, it takes approximately 4–7 weeks. Some centers may arrange biopsy and subsequent transfer preparation within the same cycle, but most cases require two separate cycles (one for testing, the next for the formal transfer).

5. Differences Between Hospitals and Selection Considerations

Fertility centers in Hong Kong offering ERA testing differ in the following aspects:

• Testing Laboratory: Some centers send samples to IGENOMIX (Spain), while others use US-based or local laboratories. The testing models and gene coverage may vary slightly between platforms, but the core principle remains the same.
• Endometrial Preparation Protocol Preference: Some centers favor the HRT protocol for its higher consistency; others individualize the choice based on patient characteristics.
• Biopsy Operator Experience: Differences in biopsy technique details (e.g., catheter type, sampling location, suction intensity) among centers can affect sample quality and thus test success rates.
• Additional Test Combinations: Some centers combine ERA with endometrial microbiome analysis (EMMA/ALICE) or immunohistochemistry for a more comprehensive endometrial assessment.

Patients should understand that: The test itself is highly standardized, and results are generally consistent across different laboratories. However, the endometrial preparation protocol and biopsy quality directly impact the results. Therefore, choosing an experienced fertility center and physician is more important than focusing solely on the laboratory brand.

6. Factors Influencing Cost

The total cost of ERA testing in Hong Kong comprises the following components:

Cost differences mainly arise from: the choice of testing laboratory, whether additional tests (e.g., EMMA) are combined, and the use of imported medications. It is advisable to request a detailed cost breakdown from the fertility center before deciding on the test, confirming whether all components are included.

7. Most Easily Overlooked Details

8. Frequently Asked Questions

9. Physician’s Decision Logic: When is ERA Testing Most Valuable?

From a clinical reproductive medicine decision-making perspective, the ERA test is not a “universal troubleshooting tool.” When physicians recommend ERA testing, they typically follow this logic:

• Step 1: Rule out embryo factors — Confirm that the transferred embryo is euploid (PGT-A normal) or at least a good-quality blastocyst.
• Step 2: Rule out uterine anatomical factors — Confirm via hysteroscopy that there are no polyps, adhesions, endometritis, etc.
• Step 3: Evaluate the reasonableness of the endometrial preparation protocol in previous cycles — Including progesterone dosage, administration route, endometrial thickness and pattern.
• Step 4: When the first three steps show no significant abnormalities but implantation still fails repeatedly, the clinical value of ERA testing is highest.

In other words, ERA testing is best suited as a “deep investigation tool after excluding other known factors,” rather than a first-line screening method.

10. Practitioner Observation: Practical Application Trends of ERA Testing in Hong Kong

In Hong Kong’s fertility centers, the clinical application of ERA testing shows the following characteristics:

• Increasing Application Rate: With the growing demand for individualized transfer protocols among patients with recurrent implantation failure, the recommendation rate for ERA testing has risen from less than 10% five years ago to the current 25%–30%.
• Combined Use with PGT-A: An increasing number of centers combine ERA with preimplantation genetic testing for aneuploidy (PGT-A) for older patients or those with recurrent implantation failure, forming a dual-dimensional assessment system of “embryo + endometrium.”
• Faster Local Testing: Previously, samples had to be sent overseas, leading to longer logistics and customs clearance times. In the past two years, some laboratories have begun offering local testing services, shortening the report turnaround time to 7–10 business days.
• Increased Patient Awareness: Through patient education by fertility centers and online knowledge dissemination, the number of patients proactively inquiring about ERA testing has significantly increased. However, approximately 40% of patients still have misconceptions about the test’s principles and indications.

Checklist Reminder: Before considering ERA testing, it is recommended to complete the following basic evaluations: hysteroscopy, endometrial biopsy pathology (to rule out chronic endometritis), karyotype analysis of both partners, and a review of PGT-A results for previous embryos. These results can provide a more complete basis for deciding on the necessity of ERA testing.